<?xml version='1.0' encoding='utf-8'?>
<document id="29920736"><sentence text="Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study."><entity charOffset="20-30" id="DDI-PubMed.29920736.s1.e0" text="probenecid" /><entity charOffset="35-45" id="DDI-PubMed.29920736.s1.e1" text="cimetidine" /><entity charOffset="51-62" id="DDI-PubMed.29920736.s1.e2" text="mirogabalin" /><pair ddi="false" e1="DDI-PubMed.29920736.s1.e0" e2="DDI-PubMed.29920736.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29920736.s1.e0" e2="DDI-PubMed.29920736.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29920736.s1.e0" e2="DDI-PubMed.29920736.s1.e2" /><pair ddi="false" e1="DDI-PubMed.29920736.s1.e1" e2="DDI-PubMed.29920736.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29920736.s1.e1" e2="DDI-PubMed.29920736.s1.e2" /></sentence><sentence text="The primary aim of this study was to assess the individual effects of probenecid and cimetidine on mirogabalin exposure"><entity charOffset="70-80" id="DDI-PubMed.29920736.s2.e0" text="probenecid" /><entity charOffset="85-95" id="DDI-PubMed.29920736.s2.e1" text="cimetidine" /><entity charOffset="99-110" id="DDI-PubMed.29920736.s2.e2" text="mirogabalin" /><pair ddi="false" e1="DDI-PubMed.29920736.s2.e0" e2="DDI-PubMed.29920736.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29920736.s2.e0" e2="DDI-PubMed.29920736.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29920736.s2.e0" e2="DDI-PubMed.29920736.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29920736.s2.e1" e2="DDI-PubMed.29920736.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29920736.s2.e1" e2="DDI-PubMed.29920736.s2.e2" /></sentence><sentence text="" /><sentence text="This phase 1, open-label, crossover study randomized healthy adults to receive three treatment regimens, each separated by ≥5-day washout: a single oral dose of mirogabalin 15 mg on day 2, mirogabalin 15 mg on day 2 plus probenecid 500 mg every 6 h from days 1 to 4, and mirogabalin 15 mg on day 2 plus cimetidine 400 mg every 6 h from days 1 to 4"><entity charOffset="161-172" id="DDI-PubMed.29920736.s4.e0" text="mirogabalin" /><entity charOffset="221-231" id="DDI-PubMed.29920736.s4.e1" text="probenecid" /><entity charOffset="271-282" id="DDI-PubMed.29920736.s4.e2" text="mirogabalin" /><entity charOffset="303-313" id="DDI-PubMed.29920736.s4.e3" text="cimetidine" /><pair ddi="false" e1="DDI-PubMed.29920736.s4.e0" e2="DDI-PubMed.29920736.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29920736.s4.e0" e2="DDI-PubMed.29920736.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29920736.s4.e0" e2="DDI-PubMed.29920736.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29920736.s4.e0" e2="DDI-PubMed.29920736.s4.e3" /><pair ddi="false" e1="DDI-PubMed.29920736.s4.e1" e2="DDI-PubMed.29920736.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29920736.s4.e1" e2="DDI-PubMed.29920736.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29920736.s4.e1" e2="DDI-PubMed.29920736.s4.e3" /><pair ddi="false" e1="DDI-PubMed.29920736.s4.e2" e2="DDI-PubMed.29920736.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29920736.s4.e2" e2="DDI-PubMed.29920736.s4.e3" /></sentence><sentence text="" /><sentence text="Coadministration of mirogabalin with probenecid or cimetidine increased the maximum and total mirogabalin exposure"><entity charOffset="20-31" id="DDI-PubMed.29920736.s6.e0" text="mirogabalin" /><entity charOffset="37-47" id="DDI-PubMed.29920736.s6.e1" text="probenecid" /><entity charOffset="51-61" id="DDI-PubMed.29920736.s6.e2" text="cimetidine" /><entity charOffset="94-105" id="DDI-PubMed.29920736.s6.e3" text="mirogabalin" /><pair ddi="false" e1="DDI-PubMed.29920736.s6.e0" e2="DDI-PubMed.29920736.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29920736.s6.e0" e2="DDI-PubMed.29920736.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29920736.s6.e0" e2="DDI-PubMed.29920736.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29920736.s6.e0" e2="DDI-PubMed.29920736.s6.e3" /><pair ddi="false" e1="DDI-PubMed.29920736.s6.e1" e2="DDI-PubMed.29920736.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29920736.s6.e1" e2="DDI-PubMed.29920736.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29920736.s6.e1" e2="DDI-PubMed.29920736.s6.e3" /><pair ddi="false" e1="DDI-PubMed.29920736.s6.e2" e2="DDI-PubMed.29920736.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29920736.s6.e2" e2="DDI-PubMed.29920736.s6.e3" /></sentence><sentence text=" The geometric mean ratios of Cmax and AUC(0-t) (90% CI) with and without coadministration of probenecid were 128"><entity charOffset="94-104" id="DDI-PubMed.29920736.s7.e0" text="probenecid" /></sentence><sentence text="7% (121" /><sentence text="9-135" /><sentence text="7%) and 176" /><sentence text="1% (171" /><sentence text="9-180" /><sentence text="3%), respectively" /><sentence text=" The geometric mean ratios of Cmax and AUC(0-t) (90% CI) with and without coadministration of cimetidine were 117"><entity charOffset="94-104" id="DDI-PubMed.29920736.s14.e0" text="cimetidine" /></sentence><sentence text="1% (111" /><sentence text="0-123" /><sentence text="6%) and 143" /><sentence text="7% (140" /><sentence text="3-147" /><sentence text="2%), respectively" /><sentence text=" Mean (standard deviation) renal clearance of mirogabalin (l h-1 ) was substantially slower after probenecid [6"><entity charOffset="46-57" id="DDI-PubMed.29920736.s21.e0" text="mirogabalin" /></sentence><sentence text="67 (1" /><sentence text="53)] or cimetidine [7"><entity charOffset="8-18" id="DDI-PubMed.29920736.s23.e0" text="cimetidine" /></sentence><sentence text="17 (1" /><sentence text="68)] coadministration, compared with mirogabalin alone [11"><entity charOffset="37-48" id="DDI-PubMed.29920736.s25.e0" text="mirogabalin" /></sentence><sentence text="3 (2" /><sentence text="39)]" /><sentence text=" Coadministration of probenecid or cimetidine decreased mirogabalin mean (standard deviation) apparent total body clearance [10"><entity charOffset="21-31" id="DDI-PubMed.29920736.s28.e0" text="probenecid" /><entity charOffset="35-45" id="DDI-PubMed.29920736.s28.e1" text="cimetidine" /><pair ddi="false" e1="DDI-PubMed.29920736.s28.e0" e2="DDI-PubMed.29920736.s28.e0" /><pair ddi="false" e1="DDI-PubMed.29920736.s28.e0" e2="DDI-PubMed.29920736.s28.e1" /></sentence><sentence text="5 (2" /><sentence text="33) and 12" /><sentence text="8 (2" /><sentence text="67) l h-1 , respectively, vs" /><sentence text=" 18" /><sentence text="4 (3" /><sentence text="93) for mirogabalin alone]" /><sentence text="" /><sentence text="A greater magnitude of change in mirogabalin exposure was observed when coadministered with a drug that inhibits both renal and metabolic clearance (probenecid) vs" /><sentence text=" a drug that only affects renal clearance (cimetidine)"><entity charOffset="43-53" id="DDI-PubMed.29920736.s38.e0" text="cimetidine" /></sentence><sentence text=" However, as the increase in exposure is not clinically significant (&gt;2-fold), no a priori dose adjustment is recommended" /><sentence text="" /></document>